Adjuvant Treatment Approaches after Radical Prostatectomy with Lymph Node Involvement
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: The aim of this study was to evaluate the adjuvant treatment preferences and effects on disease progression in patients with pathologically positive lymph node prostate cancer. METHODS: Patients who underwent radical prostatectomy from the prostate cancer database of the Turkish Urooncology Association with lymph node involvement were included in the study. Database includes prostate cancer patients from many experience Urooncology centers of Turkey. Adjuvant treatment approaches and the factors that effect the PSA recurrrence was analysed. RESULTS: Postoperative median 2 (1-3) lymph nodes were found to be positive, and the median lymph node density was reported as 0.13 (0.07-0.25). Seventy-four percent of patients received adjuvant treatment postoperatively. Seventy four of the patients (46.54%) received hormonal therapy in combination with radiotherapy; 47 of them (29.55%) received only hormonal treatment and 20(12.57%) only received radiotherapy. The number of lymph nodes removed was less in the group requiring adjuvant treatment, and this group had a higher rate of surgical margin positivity and seminal vesicle invasion. In addition, adjuvant treatment group had a statistically significant higher lymph node density. There was no significant difference in Kaplan-Meier method comparing 5-year PSA recurrence-free survival in patients with and without adjuvant therapy. When the patient clustered as non-adjuvant, only hormonal therapy and hormonal therapy with radiotherapy, a significant survival advantage was found in the hormonal therapy with radiotherapy group compared to the other two groups (p=0.043). CONCLUSION: No significant difference was found between two groups in terms of time until PSA recurrence during our follow-up. In subgroup analysis survival advantage was found in the hormonal therapy with radiotherapy group compared to non-adjuvant and only hormonal therapy groups.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Adjuvant Treatment Approaches after Radical Prostatectomy with Lymph Node Involvement
- Date Crossref
- 01/07/2022
- Éditeur
- EpiSmart Science Vector Ltd
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Sağlık Bilimleri Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Manisa Celal Bayar University pays non établi dans la noticeUniversité ou école supérieure
-
Hacettepe University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Cukurova University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Ministry of Health pays non établi dans la noticeOrganisme public
-
Gazi University pays non établi dans la noticeUniversité ou école supérieure
-
Dokuz Eylül University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Marmara University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Anadolu University pays non établi dans la noticeUniversité ou école supérieure
-
Istanbul University pays non établi dans la noticeUniversité ou école supérieure
-
Ankara University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
University of Health Sciences Department of Urology pays non établi dans la noticeUniversité ou école supérieure
Sağlık Bilimleri Üniversitesi, Manisa Celal Bayar University et Department of Urology — Hacettepe University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.